Search research articles
Contact Us
Filters
Showing results (351-360 of 361) with videos related to
Page
of 37
Sort By:
JCO Precision Oncology
|
February 9, 2022
<i>EGFR</i> Genotyping of Matched Urine, Plasma, and Tumor Tissue in Patients With Non-Small-Cell Lung Cancer Treated With Rociletinib, an <i>EGFR</i> Tyrosine Kinase Inhibitor
Jonathan W Goldman, Chris Karlovich, Lecia V Sequist, et al.
JTO Clinical and Research Reports
|
November 14, 2025
Characteristics of Short-Term Survivors With <i>ALK</i> or <i>ROS1</i>-Altered Metastatic NSCLC
Kai-Lin Liu, Alex Watts, Connor B Grady, et al.
Nature Communications
|
May 28, 2026
Human forebrain neural synchronization and entrainment to breathing during wakefulness, sleep, and external mechanical ventilation
Md Rakibul Mowla, Ariane E Rhone, Sukhbinder Kumar, et al.
The New England Journal of Medicine
|
February 5, 2025
Efficacy of Zenocutuzumab in <i>NRG1</i> Fusion-Positive Cancer
Alison M Schram, Koichi Goto, Dong-Wan Kim, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
June 2, 2021
Clinicopathologic Features and Response to Therapy of <i>NRG1</i> Fusion-Driven Lung Cancers: The eNRGy1 Global Multicenter Registry
Alexander Drilon, Michael Duruisseaux, Ji-Youn Han, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 26, 2026
Final Efficacy and Safety Data From the Phase I/II ARROW Study of Pralsetinib in Patients With Advanced <i>RET</i> Fusion-Positive Non-Small Cell Lung Cancer
Benjamin Besse, Vivek Subbiah, Giuseppe Curigliano, et al.
Cancer Discovery
|
February 11, 2017
Safety and Antitumor Activity of the Multitargeted Pan-TRK, ROS1, and ALK Inhibitor Entrectinib: Combined Results from Two Phase I Trials (ALKA-372-001 and STARTRK-1)
Alexander Drilon, Salvatore Siena, Sai-Hong Ignatius Ou, et al.
The Lancet. Oncology
|
December 16, 2019
Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1-2 trials
Robert C Doebele, Alexander Drilon, Luis Paz-Ares, et al.
Cancer Discovery
|
April 2, 2024
Activating Point Mutations in the MET Kinase Domain Represent a Unique Molecular Subset of Lung Cancer and Other Malignancies Targetable with MET Inhibitors
Federica Pecci, Seshiru Nakazawa, Biagio Ricciuti, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
January 15, 2026
Landscape of Genomic Mechanisms of Resistance to Selective RET Inhibitors in RET-Altered Solid Tumors: Analysis of the RETgistry Global Consortium
Sarah Waliany, Alissa J Cooper, Stephen V Liu, et al.
Page
of 37
Search research articles
Search
Showing results (351-360 of 361) with videos related to
Sort By:
Page
of 37
JCO Precision Oncology
|
February 9, 2022
<i>EGFR</i> Genotyping of Matched Urine, Plasma, and Tumor Tissue in Patients With Non-Small-Cell Lung Cancer Treated With Rociletinib, an <i>EGFR</i> Tyrosine Kinase Inhibitor
Jonathan W Goldman, Chris Karlovich, Lecia V Sequist, et al.
JTO Clinical and Research Reports
|
November 14, 2025
Characteristics of Short-Term Survivors With <i>ALK</i> or <i>ROS1</i>-Altered Metastatic NSCLC
Kai-Lin Liu, Alex Watts, Connor B Grady, et al.
Nature Communications
|
May 28, 2026
Human forebrain neural synchronization and entrainment to breathing during wakefulness, sleep, and external mechanical ventilation
Md Rakibul Mowla, Ariane E Rhone, Sukhbinder Kumar, et al.
The New England Journal of Medicine
|
February 5, 2025
Efficacy of Zenocutuzumab in <i>NRG1</i> Fusion-Positive Cancer
Alison M Schram, Koichi Goto, Dong-Wan Kim, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
June 2, 2021
Clinicopathologic Features and Response to Therapy of <i>NRG1</i> Fusion-Driven Lung Cancers: The eNRGy1 Global Multicenter Registry
Alexander Drilon, Michael Duruisseaux, Ji-Youn Han, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 26, 2026
Final Efficacy and Safety Data From the Phase I/II ARROW Study of Pralsetinib in Patients With Advanced <i>RET</i> Fusion-Positive Non-Small Cell Lung Cancer
Benjamin Besse, Vivek Subbiah, Giuseppe Curigliano, et al.
Cancer Discovery
|
February 11, 2017
Safety and Antitumor Activity of the Multitargeted Pan-TRK, ROS1, and ALK Inhibitor Entrectinib: Combined Results from Two Phase I Trials (ALKA-372-001 and STARTRK-1)
Alexander Drilon, Salvatore Siena, Sai-Hong Ignatius Ou, et al.
The Lancet. Oncology
|
December 16, 2019
Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1-2 trials
Robert C Doebele, Alexander Drilon, Luis Paz-Ares, et al.
Cancer Discovery
|
April 2, 2024
Activating Point Mutations in the MET Kinase Domain Represent a Unique Molecular Subset of Lung Cancer and Other Malignancies Targetable with MET Inhibitors
Federica Pecci, Seshiru Nakazawa, Biagio Ricciuti, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
January 15, 2026
Landscape of Genomic Mechanisms of Resistance to Selective RET Inhibitors in RET-Altered Solid Tumors: Analysis of the RETgistry Global Consortium
Sarah Waliany, Alissa J Cooper, Stephen V Liu, et al.
Page
of 37